Neurocrine Biosciences Inc vs Nuscale Power Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Nuscale Power Corporation trades at $8.81 (market cap $2.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.3× Nuscale Power Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| NBIX | SMR | |
|---|---|---|
Market Cap | $17.40B | $2.76B |
Sector | Health | Utilities |
52-Week High | $180.55 | $53.43 |
52-Week Low | $123.10 | $7.64 |
Enterprise Value | $16.49B | $1.87B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →